ACOX1

Across TCGA pan-cancer cohorts, ACOX1 mass-spec protein differs between tumor and matched normal tissue in 6 of 18 cancer types tested, making tumor–normal expression one of ACOX1’s most consistent transcriptional readouts.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where ACOX1 mass-spec protein is repressed in tumor relative to normal tissue. In most cancer types ACOX1 is over-expressed in tumor, although a few such as CCRCC and HNSC show the opposite, repressed pattern.

CCRCC, PDAC, and HNSC are the cancer types where ACOX1 tumor–normal differential expression is most reproducible.

mass-spec protein tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in ACOX1 mass-spec protein (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
CCRCC	Male	All	−1.552	<.001	12	view →
PDAC	Female	II,III,IV	+0.479	<.001	9	view →
HNSC	Male	All	−0.215	.001	8	view →
COAD	All	All	−0.250	<.001	6	view →
OV	All	All	+0.429	.048	2	view →
LUAD	Female	III,IV	+0.248	.010	1	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 6 strongest of 6 lineages.

ACOX1–CCRCC

Open the CCRCC breakdown →